{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:55:45Z","timestamp":1790549745732,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010239","name":"Korea Carbon Capture and Sequestration R and D Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023231","name":"National Institute for International Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tissue Eng Regen Med"],"DOI":"10.1007\/s13770-026-00837-x","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:16:00Z","timestamp":1790486160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Promoter-Targeted CRISPR Correction of PMP22 Gene Dosage Restores Schwann Cell Homeostasis in Charcot\u2013Marie\u2013Tooth Disease Type 1A"],"prefix":"10.1007","author":[{"given":"Hyun Myung","family":"Doo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Hyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Ok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1055\/s-0039-1693006","volume":"39","author":"AS Carroll","year":"2019","unstructured":"Carroll AS, Burns J, Nicholson G, Kiernan MC, Vucic S. Inherited neuropathies. Semin Neurol. 2019;39:620\u201339.","journal-title":"Semin Neurol"},{"key":"837_CR2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/nar\/gkaa956","volume":"48","author":"JS Lee","year":"2020","unstructured":"Lee JS, Lee JY, Song DW, Bae HS, Doo HM, Yu HS, et al. Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot\u2013Marie\u2013Tooth disease type 1A in mice. Nucleic Acids Res. 2020;48:130\u201340.","journal-title":"Nucleic Acids Res"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1038\/s41467-018-05420-0","volume":"9","author":"R Fledrich","year":"2018","unstructured":"Fledrich R, Abdelaal T, Rasch L, Bansal V, Schutza V, Brugger B, et al. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun. 2018;9:3025.","journal-title":"Nat Commun"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1212\/WNL.0000000000009035","volume":"94","author":"V Fridman","year":"2020","unstructured":"Fridman V, Sillau S, Acsadi G, Bacon C, Dooley K, Burns J, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020;94:e884\u201396.","journal-title":"Neurology"},{"key":"837_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","volume":"16","author":"S Attarian","year":"2021","unstructured":"Attarian S, Young P, Brannagan TH, Adams D, Van Damme P, Thomas FP, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis. 2021;16:433.","journal-title":"Orphanet J Rare Dis"},{"key":"837_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s13760-025-02881-1","volume":"125","author":"H Qi","year":"2025","unstructured":"Qi H, Wang X, Wu B, Chen J, Zhang G. The current status of Charcot-Marie-Tooth disease type 1A treatment. Acta Neurol Belg. 2025;125:1525\u201333.","journal-title":"Acta Neurol Belg"},{"key":"837_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2013.3178","volume":"70","author":"RA Lewis","year":"2013","unstructured":"Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70:981\u20137.","journal-title":"JAMA Neurol"},{"key":"837_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1177\/0963689718775406","volume":"27","author":"CY Chang","year":"2018","unstructured":"Chang CY, Ting HC, Liu CA, Su HL, Chiou TW, Harn HJ, et al. Induced pluripotent stem cells: a powerful neurodegenerative disease modeling tool for mechanism study and drug discovery. Cell Transplant. 2018;27:1588\u2013602.","journal-title":"Cell Transplant"},{"key":"837_CR9","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1098\/rstb.2011.0017","volume":"366","author":"JJ Unternaehrer","year":"2011","unstructured":"Unternaehrer JJ, Daley GQ. Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci. 2011;366:2274\u201385.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"837_CR10","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/brain\/awac475","volume":"146","author":"J Van Lent","year":"2023","unstructured":"Van Lent J, Vendredy L, Adriaenssens E, Da Silva Authier T, Asselbergh B, Kaji M, et al. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A. Brain. 2023;146:2885\u201396.","journal-title":"Brain"},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s43856-023-00400-y","volume":"3","author":"Y Yoshioka","year":"2023","unstructured":"Yoshioka Y, Taniguchi JB, Homma H, Tamura T, Fujita K, Inotsume M, et al. AAV-mediated editing of PMP22 rescues Charcot\u2013Marie\u2013Tooth disease type 1A features in patient-derived iPS Schwann cells. Commun Med (Lond). 2023;3:170.","journal-title":"Commun Med (Lond)"},{"key":"837_CR12","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1093\/hmg\/ddw209","volume":"25","author":"SJ Chamberlain","year":"2016","unstructured":"Chamberlain SJ. Disease modelling using human iPSCs. Hum Mol Genet. 2016;25:R173\u201381.","journal-title":"Hum Mol Genet"},{"key":"837_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8:36.","journal-title":"Signal Transduct Target Ther"},{"key":"837_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/genes16111279","volume":"16","author":"CA Cesaroni","year":"2025","unstructured":"Cesaroni CA, Caiazza L, Pisano G, Gnazzo M, Sigona G, Rizzi S, et al. PMP22-related neuropathies: a systematic review. Genes (Basel). 2025;16:1279.","journal-title":"Genes (Basel)"},{"key":"837_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41467-020-14362-5","volume":"11","author":"K Li","year":"2020","unstructured":"Li K, Liu Y, Cao H, Zhang Y, Gu Z, Liu X, et al. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing. Nat Commun. 2020;11:485.","journal-title":"Nat Commun"},{"key":"837_CR16","doi-asserted-by":"publisher","first-page":"eaau0629","DOI":"10.1126\/science.aau0629","volume":"363","author":"N Matharu","year":"2019","unstructured":"Matharu N, Rattanasopha S, Tamura S, Maliskova L, Wang Y, Bernard A, et al. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science. 2019;363:eaau0629.","journal-title":"Science"},{"key":"837_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490\u20135.","journal-title":"Nature"},{"key":"837_CR18","doi-asserted-by":"publisher","first-page":"e159814","DOI":"10.1172\/JCI159814","volume":"132","author":"M Stavrou","year":"2022","unstructured":"Stavrou M, Kagiava A, Choudury SG, Jennings MJ, Wallace LM, Fowler AM, et al. A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice. J Clin Invest. 2022;132:e159814.","journal-title":"J Clin Invest"},{"key":"837_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.stem.2016.04.013","volume":"18","author":"D Hockemeyer","year":"2016","unstructured":"Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. Cell Stem Cell. 2016;18:573\u201386.","journal-title":"Cell Stem Cell"},{"key":"837_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593:429\u201334.","journal-title":"Nature"},{"key":"837_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","volume":"10","author":"D Pareyson","year":"2011","unstructured":"Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10:320\u20138.","journal-title":"Lancet Neurol"},{"key":"837_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1172\/JCI96499","volume":"128","author":"HT Zhao","year":"2018","unstructured":"Zhao HT, Damle S, Ikeda-Lee K, Kuntz S, Li J, Mohan A, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest. 2018;128:359\u201368.","journal-title":"J Clin Invest"},{"key":"837_CR23","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bph.15231","volume":"177","author":"N Ha","year":"2020","unstructured":"Ha N, Choi YI, Jung N, Song JY, Bae DK, Kim MC, et al. A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A. Br J Pharmacol. 2020;177:5096\u2013113.","journal-title":"Br J Pharmacol"},{"key":"837_CR24","doi-asserted-by":"publisher","first-page":"e2101308","DOI":"10.1002\/adbi.202101308","volume":"6","author":"AST Smith","year":"2022","unstructured":"Smith AST, Kim JH, Chun C, Gharai A, Moon HW, Kim EY, et al. HDAC6 inhibition corrects electrophysiological and axonal transport deficits in a human stem cell-based model of Charcot-Marie-Tooth disease (type 2D). Adv Biol (Weinh). 2022;6:e2101308.","journal-title":"Adv Biol (Weinh)"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"146625","DOI":"10.1016\/j.brainres.2019.146625","volume":"1729","author":"AM Rossor","year":"2020","unstructured":"Rossor AM, Shy ME, Reilly MM. Are we prepared for clinical trials in Charcot-Marie-Tooth disease? Brain Res. 2020;1729:146625.","journal-title":"Brain Res"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4103\/1673-5374.361538","volume":"18","author":"M Stavrou","year":"2023","unstructured":"Stavrou M, Kleopa KA. CMT1A current gene therapy approaches and promising biomarkers. Neural Regen Res. 2023;18:1434\u201340.","journal-title":"Neural Regen Res"},{"key":"837_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s42003-021-01839-2","volume":"4","author":"S Boutary","year":"2021","unstructured":"Boutary S, Caillaud M, El Madani M, Vallat JM, Loisel-Duwattez J, Rouyer A, et al. Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1A. Commun Biol. 2021;4:317.","journal-title":"Commun Biol"},{"key":"837_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41467-025-67256-9","volume":"17","author":"T Burgold","year":"2026","unstructured":"Burgold T, Karakoc E, Goncalves E, Barrio-Hernandez I, Dwane L, Silva R, et al. A next-generation dual guide CRISPR system for genetic interaction library screening. Nat Commun. 2026;17:561.","journal-title":"Nat Commun"},{"key":"837_CR29","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1523\/JNEUROSCI.5893-10.2011","volume":"31","author":"EA Jones","year":"2011","unstructured":"Jones EA, Lopez-Anido C, Srinivasan R, Krueger C, Chang LW, Nagarajan R, et al. Regulation of the PMP22 gene through an intronic enhancer. J Neurosci. 2011;31:4242\u201350.","journal-title":"J Neurosci"},{"key":"837_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12035-012-8370-x","volume":"47","author":"J Li","year":"2013","unstructured":"Li J, Parker B, Martyn C, Natarajan C, Guo J. The PMP22 gene and its related diseases. Mol Neurobiol. 2013;47:673\u201398.","journal-title":"Mol Neurobiol"},{"key":"837_CR31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s42003-022-03977-7","volume":"5","author":"HT Zhao","year":"2022","unstructured":"Zhao HT, Kuntz S, Kaphzan H, et al. Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer. Commun Biol. 2022;5:1032.","journal-title":"Commun Biol"},{"key":"837_CR32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/1097-4547(20000815)61:4<443::AID-JNR11>3.0.CO;2-W","volume":"61","author":"D Saberan-Djoneidi","year":"2000","unstructured":"Saberan-Djoneidi D, Soussi-Yanicostas N, Poras I, Abitbol M, Suter U, Ghandour MS. Regulation of PMP22 gene expression in Schwann cells: characterization of two promoters. J Neurosci Res. 2000;61:443\u201352.","journal-title":"J Neurosci Res"},{"key":"837_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1044-7431(03)00246-X","volume":"24","author":"M Maier","year":"2003","unstructured":"Maier M, Castagner F, Berger P, Suter U. Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons. Mol Cell Neurosci. 2003;24:803\u201317.","journal-title":"Mol Cell Neurosci"},{"key":"837_CR34","doi-asserted-by":"publisher","first-page":"E2421","DOI":"10.1073\/pnas.1522202113","volume":"113","author":"A Kagiava","year":"2016","unstructured":"Kagiava A, Sargiannidou I, Theophilidis G, Karaiskos C, Richter J, Bashiardes S, et al. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc Natl Acad Sci USA. 2016;113:E2421\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"837_CR35","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.ynpai.2020.100055","volume":"8","author":"A Lampert","year":"2020","unstructured":"Lampert A, Bennett DL, McDermott LA, Neureiter A, Eberhardt E, Winner B, et al. Human sensory neurons derived from pluripotent stem cells for disease modelling and personalized medicine. Neurobiol Pain. 2020;8:100055.","journal-title":"Neurobiol Pain"},{"key":"837_CR36","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1093\/brain\/awae158","volume":"147","author":"R Prior","year":"2024","unstructured":"Prior R, Silva A, Vangansewinkel T, Idkowiak J, Tharkeshwar AK, Hellings TP, et al. PMP22 duplication dysregulates lipid homeostasis and plasma membrane organization in developing human Schwann cells. Brain. 2024;147:3113\u201330.","journal-title":"Brain"},{"key":"837_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/jnnp-2018-318834","volume":"90","author":"M Juneja","year":"2019","unstructured":"Juneja M, Burns J, Saporta MA, Timmerman V. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry. 2019;90:58\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"837_CR38","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/joa.13606","volume":"241","author":"S Negro","year":"2022","unstructured":"Negro S, Pirazzini M, Rigoni M. Models and methods to study Schwann cells. J Anat. 2022;241:1235\u201358.","journal-title":"J Anat"},{"key":"837_CR39","doi-asserted-by":"publisher","first-page":"eabd9749","DOI":"10.1126\/sciadv.abd9749","volume":"7","author":"S Hyung","year":"2021","unstructured":"Hyung S, Lee SR, Kim J, Kim Y, Kim S, Kim HN, et al. A 3D disease and regeneration model of peripheral nervous system-on-a-chip. Sci Adv. 2021;7:eabd9749.","journal-title":"Sci Adv"},{"key":"837_CR40","doi-asserted-by":"publisher","first-page":"120230","DOI":"10.1016\/j.biomaterials.2020.120230","volume":"257","author":"A Malheiro","year":"2020","unstructured":"Malheiro A, Morgan F, Baker M, Moroni L, Wieringa P. A three-dimensional biomimetic peripheral nerve model for drug testing and disease modelling. Biomaterials. 2020;257:120230.","journal-title":"Biomaterials"},{"key":"837_CR41","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","volume":"12","author":"B Gautier","year":"2021","unstructured":"Gautier B, Hajjar H, Soares S, Berthelot J, Deck M, Abbou S, et al. AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot\u2013Marie\u2013Tooth disease type 1A. Nat Commun. 2021;12:2356.","journal-title":"Nat Commun"}],"container-title":["Tissue Engineering and Regenerative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13770-026-00837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13770-026-00837-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13770-026-00837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:02:15Z","timestamp":1790546535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13770-026-00837-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":41,"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s13770-026-00837-x","relation":{},"ISSN":["1738-2696","2212-5469"],"issn-type":[{"value":"1738-2696","type":"print"},{"value":"2212-5469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Sungkyunkwan University, Samsung Medical Center (2014\u201308-057-002). Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) solely for English language editing, including grammar refinement and improvement of readability. The authors critically reviewed and revised all AI-assisted text and take full responsibility for the final content of the manuscript.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}